18 results
First part of study (Phase 1)Aim: To evaluate the efficacy of ileal brake activation, by ingestion of an encapsulated nutrient mixture delivered to the stomach (placebo) or distal small intestine (active) analysed by the amount of food consumed…
Based on the data available, Anamorelin HCl produces an increase in total body weight and Lean Body Mass in patients with advanced cancer, and specifically in patients with NSCLC, in addition to increasing muscle strength and improving quality of…
Primary objective• To assess the effect of HM11260C, in combination with a hypocaloric diet, on body weight over the 20 weeks from baseline in obese subjectsSecondary objectives• To assess the safety, tolerability, and immunogenicity of HM11260C, in…
Aim: To determine the effect of repetitive ileal brake activation on food intake, satiety, gastrointestinal peptide release (CCK, GLP-1, PYY, glucose and insulin) and gut motilityHypothesis: We hypothesize that after repetitive ileal infusion of…
Study A:Aim: To investigate the location specific differences (duodenum, jejunum and ileum) of casein infusion on ad libitum food intake, satiety scores and the release of gastrointestinal peptides , associated with food intake and satiety (CCK, GLP…
The primary objective of the present study is to investigate the effect of the fat emulsion on energy intake at lunch.
To investigate the long-term effects of green tea on gut flora, fat absorption, resting energy expenditure and body composition.
Based on the data available, Anamorelin HCl produces an increase in total body weight and Lean Body Mass in patients with advanced cancer, and specifically in patients with NSCLC, in addition to increasing muscle strength and improving quality of…
To establish the efficacy of 60 mg baclofen compared to placebo in inducing a decrease in food craving, as assessed by a food craving questionnaires (G-FCQ-T) over 6 months in obese subjects.
To investigate the effect of low-dose long acting insulin therapy on nutritional status in adult CF patients without diabetes.
The primary objective of the study is to find the appropriate, clinically relevant dosages (among the 5, 10, and 15 mg twice-daily dosages) of JNJ-16269110 by assessing mean changes in body weight from baseline to Week 12, compared to placebo .The…
Primary objective1. To investigate whether TM38837 attenuates the central effects of THCSecondary objectives2. To explore the effect of TM38837 on THC induced effects on heart rate3. To investigate the effect of 60 mg rimonabant on THC-induced CNS…
To determine the safety and tolerability of P1201-07 administered as single ascending oral doses in overweight or obese but otherwise healthy subjects.
This Phase 2b/3 double-blind, placebo-controlled study will evaluate the safety, tolerability, and effects of livoletide on food-related behaviors in patients with Prader-Willi Syndrome (PWS).
We hypothesize that intragastric infusion of lidocaine will result in a delay of postprandial satiation and hereby an increase in food intake at an ad libitum meal. Furthermore, we hypothesize that lidocaine infusion will not result in an increase…
The overall purpose of this trial is to assess the efficacy on weight loss and maintenance, and tolerability of four different doses of BI 456906 compared to placebo in patients with obesity or overweight (BMI >= 27kg/m2), without type 1 or…
The main purpose of this trial is to find out if an investigational drug called setmelanotide (RM-493), which mimics MSH, can help control body weight. The efficacy of setmelanotide will be compared to the efficacy of a placebo during 4 to 8 weeks.
Primary objective- To compare the efficacy of liraglutide versus placebo on weight loss in obese paediatric subjects with PWS at 16 weeks and versus no treatment at 52 weeks.Secondary objectives - To compare the efficacy of liraglutide versus…